Member

Such specialty leads therefore already exist. They do not exist courtesy of specific legislation requiring that they exist; they already exist under the NIHR. Why has the NIHR not appointed such a specialty lead to deal with rare cancers? Why is it necessary for us to legislate to require that, but in weak legislation that does not set out any timetable for the making of that appointment? That, in my view, is another reason for tightening up the Bill.